Pegcetacoplan-Empaveli usage and dosage

Pegcetacoplan is an innovative C3 complement inhibitor with the trade name Empaveli. It is mainly used to treat paroxysmal nocturnal hemoglobinuria (PNH) and C3 nephropathy/immune complex membranous glomerulonephritis (C3G/IC-MPGN). Its unique mechanism of action reduces red blood cell destruction and inflammatory response by inhibiting the activation of C3 complement, thereby improving hemolysis and kidney damage. The drug is administered by subcutaneous injection, allowing patients to undergo long-term treatment in a home environment, but it needs to be used in strict accordance with the recommended dosage and frequency to ensure efficacy and safety.

For adult patients with PNH, the recommended dose is 1080 mg subcutaneously twice weekly. For adult patients with C3G/IC-MPGN, the dosage regimen is the same as that of PNH to ensure that complement inhibition continues to work in the body. For pediatric patients aged 12 to 17 years old, the dose needs to be adjusted individually based on body weight: for those weighing 50 kg and above, the first, second and maintenance doses are 1080 mg; for those weighing 35 to 50 kg, the first dose is 648 mg, the second and maintenance doses are 810 mg; for those weighing less than 35 kg, the first and second doses are 540 mg, and the maintenance dose is 648 mg. This weight stratification strategy ensures that the drug can achieve optimal efficacy in different weight ranges while reducing the risk of adverse reactions.

During the period of using PegTac, patients should pay attention to the cleaning and care of the injection site, follow the treatment plan prescribed by the doctor, and conduct regular hematology and renal function monitoring. Overseas guidelines recommend that patients should record the time and dose of each injection to ensure continuity of treatment and facilitate follow-up evaluation by doctors. Rational use of Pegtak can not only effectively control hemolysis and renal lesions, but also significantly improve patients' quality of life and daily functions, providing a reliable long-term management solution for patients with PNH and C3G/IC-MPGN.

Reference materials:https://empaveli.com/